Mr 1257 MS

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H598162

CAS#: 61799-82-4

Description: Mr 1257 MS is a morphine antagonist.


Chemical Structure

img
Mr 1257 MS
CAS# 61799-82-4

Theoretical Analysis

Hodoodo Cat#: H598162
Name: Mr 1257 MS
CAS#: 61799-82-4
Chemical Formula: C22H29NO5S
Exact Mass: 419.18
Molecular Weight: 419.530
Elemental Analysis: C, 62.98; H, 6.97; N, 3.34; O, 19.07; S, 7.64

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mr 1257 MS;

IUPAC/Chemical Name: (4bR,8aR,9R)-11-(furan-3-ylmethyl)-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthren-3-ol methanesulfonate

InChi Key: BKGIERMBUHQGMY-LWBVMVAASA-N

InChi Code: InChI=1S/C21H25NO2.CH4O3S/c23-17-5-4-16-11-20-18-3-1-2-7-21(18,19(16)12-17)8-9-22(20)13-15-6-10-24-14-15;1-5(2,3)4/h4-6,10,12,14,18,20,23H,1-3,7-9,11,13H2;1H3,(H,2,3,4)/t18-,20+,21+;/m0./s1

SMILES Code: Oc1cc([C@]23[C@H]([C@H](N(Cc4cocc4)CC3)C5)CCCC2)c5cc1.O=S(O)(C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 419.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. PubMed PMID: 25184630; PubMed Central PMCID: PMC4201502.

2: Mattam U, Jagota A. Differential role of melatonin in restoration of age-induced alterations in daily rhythms of expression of various clock genes in suprachiasmatic nucleus of male Wistar rats. Biogerontology. 2014 Jun;15(3):257-68. doi: 10.1007/s10522-014-9495-2. Epub 2014 Mar 12. PubMed PMID: 24619734.

3: Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 2003 Aug;60(8):1073-81. PubMed PMID: 12925362.

4: Mine T, Tanaka H, Ishida Y, Imamura R, Seki K, Taguchi T. Juvenile rheumatoid arthritis manifesting in only limping due to flexion contraction of the knee. Clin Rheumatol. 2007 Mar;26(3):433-5. Epub 2006 Jan 27. PubMed PMID: 16440136.

5: Li G, Miskimen KL, Wang Z, Xie XY, Brenzovich J, Ryan JJ, Tse W, Moriggl R, Bunting KD. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood. 2010 Feb 18;115(7):1416-24. doi: 10.1182/blood-2009-07-234963. Epub 2009 Dec 14. PubMed PMID: 20008792; PubMed Central PMCID: PMC2826763.

6: Simões-Wüst AP, Sigrist B, Belyanskaya L, Hopkins Donaldson S, Stahel RA, Zangemeister-Wittke U. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J Neurooncol. 2005 Mar;72(1):29-34. PubMed PMID: 15803372.

7: Jia D, Heersche JN. Expression of insulin-like growth factor system constituents in differentiating rat osteoblastic cell populations. Growth Horm IGF Res. 2002 Dec;12(6):399-410. PubMed PMID: 12423625.